HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
Open Access
- 28 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Bioengineering and Biotechnology
- Vol. 10, 1015295
Abstract
Efficacy of anti-human epidermal growth factor receptor 2 (HER2) treatment is impacted by tissue-based evaluation bias due to tumor heterogeneity and dynamic changes of HER2 in breast cancer. Circulating tumor cell (CTC)-based HER2 phenotyping provides integral and real-time assessment, benefiting accurate HER2 diagnosis. This study developed a semi-quantitative fluorescent evaluation system of HER2 immunostaining on CTCs by peptide-functionalized magnetic nanoparticles (Pep@MNPs) and immunocytochemistry (ICC). 52 newly-diagnosed advanced breast cancer patients were enrolled for blood samples before and/or after first-line treatment, including 24 patients who were diagnosed with HER2+ tumors and treated with anti-HER2 drugs. We enumerated CTCs and assessed levels of HER2 expression on CTCs in 2.0 ml whole blood. Enumerating CTCs at baseline could distinguish cancer patients (sensitivity, 69.2%; specificity, 100%). 80.8% (42/52) of patients had at least one CTCs before therapy. Patients with p = 0.046) and overall survival (medians, not yet reached; log-rank p = 0.049) than those with ≥3 CTCs. Both HER2+ and HER2-low patients could be detected with HER2 overexpression on CTCs (CTC-HER2+) (52.6%, 44.4%, respectively), whereas all the HER2-negative patients had no CTC-HER2+ phenotype. Among HER2+ patients with ≥3 CTCs at baseline, objective response only appeared in pretherapeutic CTC-HER2+ cohort (60.0%), rather than in CTC-HER2– cohort (0.0%) (p = 0.034). In conclusion, we demonstrate the significance of CTC enumeration in diagnosis and prognosis of first-line advanced breast cancer, and highlight the value of CTC-HER2 status in predicting efficacy of anti-HER2 treatment.Keywords
Funding Information
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- National Natural Science Foundation of China
- National Natural Science Foundation of China
- Key Research Program of Frontier Science, Chinese Academy of Sciences
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
This publication has 60 references indexed in Scilit:
- Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarkerBMC Cancer, 2013
- Circulating tumour cells in non-metastatic breast cancer: a prospective studyThe Lancet Oncology, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAnnals of Oncology, 2011
- HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trialBreast Cancer Research and Treatment, 2010
- Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patientsBreast Cancer Research and Treatment, 2009
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast CancerJNCI: Journal of the National Cancer Institute, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 statusBreast Cancer Research, 2007
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004